Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 231

1.

Microstructural fronto-striatal and temporo-insular alterations are associated with fatigue in patients with multiple sclerosis independent of white matter lesion load and depression.

Palotai M, Cavallari M, Koubiyr I, Morales Pinzon A, Nazeri A, Healy BC, Glanz B, Weiner HL, Chitnis T, Guttmann CR.

Mult Scler. 2019 Aug 16:1352458519869185. doi: 10.1177/1352458519869185. [Epub ahead of print]

PMID:
31418637
2.

Rotating night shift work and risk of multiple sclerosis in the Nurses' Health Studies.

Papantoniou K, Massa J, Devore E, Munger KL, Chitnis T, Ascherio A, Schernhammer ES.

Occup Environ Med. 2019 Aug 12. pii: oemed-2019-106016. doi: 10.1136/oemed-2019-106016. [Epub ahead of print]

PMID:
31405910
3.

Discontinuation of disease-modifying therapy for patients with relapsing-remitting multiple sclerosis: Effect on clinical and MRI outcomes.

Yano H, Gonzalez C, Healy BC, Glanz BI, Weiner HL, Chitnis T.

Mult Scler Relat Disord. 2019 Jul 25;35:119-127. doi: 10.1016/j.msard.2019.07.021. [Epub ahead of print]

PMID:
31374460
4.

A 10-year study of the etiopathogenesis of cysts with a study of seromucinous glands in vocal folds.

Nerurkar NK, Chitnis T, Gupta VK, Muzumdar G, Patel K, Bhuiyan P.

Laryngoscope. 2019 Aug 1. doi: 10.1002/lary.28206. [Epub ahead of print]

PMID:
31369149
5.

Effect of assisted reproductive technology on multiple sclerosis relapses: Case series and meta-analysis.

Bove R, Rankin K, Lin C, Zhao C, Correale J, Hellwig K, Michel L, Laplaud DA, Chitnis T.

Mult Scler. 2019 Aug 1:1352458519865118. doi: 10.1177/1352458519865118. [Epub ahead of print]

PMID:
31368394
6.

Collaborative International Research in Clinical and Longitudinal Experience Study in NMOSD.

Cook LJ, Rose JW, Alvey JS, Jolley AM, Kuhn R, Marron B, Pederson M, Enriquez R, Yearley J, McKechnie S, Han MH, Tomczak AJ, Levy M, Mealy MA, Coleman J, Bennett JL, Johnson R, Barnes-Garcia M, Traboulsee AL, Carruthers RL, Lee LE, Schubert JJ, McMullen K, Kister I, Rimler Z, Reid A, Sicotte NL, Planchon SM, Cohen JA, Ivancic D, Sedlak JL, Sand IK, Repovic P, Amezcua L, Pruitt A, Amundson E, Chitnis T, Mullin DS, Klawiter EC, Russo AW, Riley CS, Onomichi KB, Levine L, Nelson KE, Nealon NM, Engel C, Kruse-Hoyer M, Marcille M, Tornes L, Rumpf A, Greer A, Kenneally Behne M, Rodriguez RR, Behne DW, Blackway DW, Coords B, Blaschke TF, Sheard J, Smith TJ, Behne JM, Yeaman MR; Guthy-Jackson Charitable Foundation International Clinical Consortium (GJCF–ICC).

Neurol Neuroimmunol Neuroinflamm. 2019 Jun 28;6(5):e583. doi: 10.1212/NXI.0000000000000583. eCollection 2019 Sep.

7.

Multiple sclerosis and sarcoidosis: A case for coexistence.

Tyshkov C, Pawate S, Bradshaw MJ, Kimbrough DJ, Chitnis T, Gelfand JM, Ryerson LZ, Kister I.

Neurol Clin Pract. 2019 Jun;9(3):218-227. doi: 10.1212/CPJ.0000000000000629.

PMID:
31341709
8.

Diagnostic Considerations in Acute Disseminated Encephalomyelitis and the Interface with MOG Antibody.

Santoro JD, Chitnis T.

Neuropediatrics. 2019 Jul 24. doi: 10.1055/s-0039-1693152. [Epub ahead of print]

PMID:
31340401
9.

Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients with Relapsing-Remitting Multiple Sclerosis: Pooled Analysis from the FREEDOMS/FREEDOMS II Trials.

Ghezzi A, Chitnis T, K-Laflamme A, Meinert R, Häring DA, Pohl D.

Neurol Ther. 2019 Jul 19. doi: 10.1007/s40120-019-0146-z. [Epub ahead of print]

PMID:
31325110
10.

miRNA contributions to pediatric-onset multiple sclerosis inferred from GWAS.

Rhead B, Shao X, Graves JS, Chitnis T, Waldman AT, Lotze T, Schreiner T, Belman A, Krupp L, Greenberg BM, Weinstock-Guttman B, Aaen G, Tillema JM, Rodriguez M, Hart J, Caillier S, Ness J, Harris Y, Rubin J, Candee MS, Gorman M, Benson L, Mar S, Kahn I, Rose J, Casper TC, Quach H, Quach D, Schaefer C, Waubant E, Barcellos LF; US Network of Pediatric MS Centers.

Ann Clin Transl Neurol. 2019 May 15;6(6):1053-1061. doi: 10.1002/acn3.786. eCollection 2019 Jun.

11.

The impact of cervical spinal cord atrophy on quality of life in multiple sclerosis.

Zurawski J, Glanz BI, Healy BC, Tauhid S, Khalid F, Chitnis T, Weiner HL, Bakshi R.

J Neurol Sci. 2019 Apr 18;403:38-43. doi: 10.1016/j.jns.2019.04.023. [Epub ahead of print]

12.

Pediatric Central Nervous System Demyelinating Diseases.

Chitnis T.

Continuum (Minneap Minn). 2019 Jun;25(3):793-814. doi: 10.1212/CON.0000000000000730.

PMID:
31162317
13.

Vitamin D genes influence MS relapses in children.

Graves JS, Barcellos LF, Krupp L, Belman A, Shao X, Quach H, Hart J, Chitnis T, Weinstock-Guttman B, Aaen G, Benson L, Gorman M, Greenberg B, Lotze T, Soe M, Ness J, Rodriguez M, Rose J, Schreiner T, Tillema JM, Waldman A, Casper TC, Waubant E.

Mult Scler. 2019 May 13:1352458519845842. doi: 10.1177/1352458519845842. [Epub ahead of print]

PMID:
31081484
14.

Clinical trials of disease-modifying agents in pediatric MS: Opportunities, challenges, and recommendations from the IPMSSG.

Waubant E, Banwell B, Wassmer E, Sormani MP, Amato MP, Hintzen R, Krupp L, Rostásy K, Tenembaum S, Chitnis T; IPMSSG.

Neurology. 2019 May 28;92(22):e2538-e2549. doi: 10.1212/WNL.0000000000007572. Epub 2019 May 1.

15.

Total intake of different minerals and the risk of multiple sclerosis.

Cortese M, Chitnis T, Ascherio A, Munger KL.

Neurology. 2019 Apr 30;92(18):e2127-e2135. doi: 10.1212/WNL.0000000000006800. Epub 2019 Apr 3.

PMID:
30944237
16.

Cross-sectional study of smoking exposure: no differential effect on OCT metrics in a cohort of MS patients.

Rosso M, Kimbrough DJ, Gonzalez CT, Glanz BI, Healy BC, Rocca MA, Filippi M, Weiner H, Chitnis T.

Mult Scler J Exp Transl Clin. 2019 Feb 25;5(1):2055217319828400. doi: 10.1177/2055217319828400. eCollection 2019 Jan-Mar.

17.

Strokelike Episodes in a Patient With Chronic Gait Abnormalities.

Santoro JD, Chitnis T.

JAMA Neurol. 2019 May 1;76(5):621-622. doi: 10.1001/jamaneurol.2019.0057. No abstract available.

PMID:
30801629
18.

Time between expanded disability status scale (EDSS) scores.

Zurawski J, Glanz BI, Chua A, Lokhande H, Rotstein D, Weiner H, Engler D, Chitnis T, Healy BC.

Mult Scler Relat Disord. 2019 May;30:98-103. doi: 10.1016/j.msard.2019.02.007. Epub 2019 Feb 5.

PMID:
30763908
19.

The neutrophil-to-lymphocyte and monocyte-to-lymphocyte ratios are independently associated with neurological disability and brain atrophy in multiple sclerosis.

Hemond CC, Glanz BI, Bakshi R, Chitnis T, Healy BC.

BMC Neurol. 2019 Feb 12;19(1):23. doi: 10.1186/s12883-019-1245-2.

20.

Admixture mapping reveals evidence of differential multiple sclerosis risk by genetic ancestry.

Chi C, Shao X, Rhead B, Gonzales E, Smith JB, Xiang AH, Graves J, Waldman A, Lotze T, Schreiner T, Weinstock-Guttman B, Aaen G, Tillema JM, Ness J, Candee M, Krupp L, Gorman M, Benson L, Chitnis T, Mar S, Belman A, Casper TC, Rose J, Moodley M, Rensel M, Rodriguez M, Greenberg B, Kahn L, Rubin J, Schaefer C, Waubant E, Langer-Gould A, Barcellos LF.

PLoS Genet. 2019 Jan 17;15(1):e1007808. doi: 10.1371/journal.pgen.1007808. eCollection 2019 Jan.

21.

A young man in "double-trouble": Hallucinations and cranial nerve palsies: From the National Multiple Sclerosis Society Case Conference Proceedings.

Bradshaw MJ, Lisak RP, Meltzer E, Melamed E, Lucas A, Freeman L, Frohman TC, Costello K, Balcer L, Galetta S, Chitnis T, Zamvil SS, Frohman EM.

Neurol Neuroimmunol Neuroinflamm. 2018 Dec 19;6(1):e526. doi: 10.1212/NXI.0000000000000526. eCollection 2019 Jan. No abstract available.

22.

Utilization Patterns of Oral Disease-Modifying Drugs in Commercially Insured Patients with Multiple Sclerosis.

Desai RJ, Mahesri M, Gagne JJ, Hurley E, Tong A, Chitnis T, Minden S, Spettell CM, Matlin OS, Shrank WH, Choudhry NK.

J Manag Care Spec Pharm. 2019 Jan;25(1):113-121. doi: 10.18553/jmcp.2019.25.1.113.

23.

Several household chemical exposures are associated with pediatric-onset multiple sclerosis.

Mar S, Liang S, Waltz M, Casper TC, Goyal M, Greenberg B, Weinstock-Guttman B, Rodriguez M, Aaen G, Belman A, Barcellos LF, Rose J, Gorman M, Benson L, Candee M, Chitnis T, Harris Y, Kahn I, Roalsted S, Hart J, Lotze T, Moodley M, Ness J, Rensel M, Rubin J, Schreiner T, Tillema JM, Waldman A, Krupp L, Graves JS, Waubant E; U.S. Network of Pediatric Multiple Sclerosis Centers.

Ann Clin Transl Neurol. 2018 Oct 9;5(12):1513-1521. doi: 10.1002/acn3.663. eCollection 2018 Dec.

24.

Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis.

Chitnis T, Gonzalez C, Healy BC, Saxena S, Rosso M, Barro C, Michalak Z, Paul A, Kivisakk P, Diaz-Cruz C, Sattarnezhad N, Pierre IV, Glanz BI, Tomic D, Kropshofer H, Häring D, Leppert D, Kappos L, Bakshi R, Weiner HL, Kuhle J.

Ann Clin Transl Neurol. 2018 Oct 16;5(12):1478-1491. doi: 10.1002/acn3.638. eCollection 2018 Dec.

25.

Food allergies are associated with increased disease activity in multiple sclerosis.

Fakih R, Diaz-Cruz C, Chua AS, Gonzalez C, Healy BC, Sattarnezhad N, Glanz BI, Weiner HL, Chitnis T.

J Neurol Neurosurg Psychiatry. 2019 Jun;90(6):629-635. doi: 10.1136/jnnp-2018-319301. Epub 2018 Dec 18.

PMID:
30563943
26.

Acquisition of Early Developmental Milestones and Need for Special Education Services in Pediatric Multiple Sclerosis.

Aaen G, Waltz M, Vargas W, Makhani N, Ness J, Harris Y, Casper TC, Benson L, Candee M, Chitnis T, Gorman M, Graves J, Greenberg B, Lotze T, Mar S, Tillema JM, Rensel M, Rodriguez M, Rose J, Rubin J, Schreiner T, Waldman A, Weinstock-Guttman B, Belman A, Waubant E, Krupp L.

J Child Neurol. 2018 Dec 17:883073818815041. doi: 10.1177/0883073818815041. [Epub ahead of print]

PMID:
30556452
27.

Beyond the band: A biomarker for pediatric MS?

Chitnis T.

Mult Scler. 2018 Nov;24(13):1655-1656. doi: 10.1177/1352458518803778. No abstract available.

PMID:
30422760
28.

Assessment of computer adaptive testing version of the Neuro-QOL for people with multiple sclerosis.

Healy BC, Zurawski J, Gonzalez CT, Chitnis T, Weiner HL, Glanz BI.

Mult Scler. 2018 Nov 1:1352458518810159. doi: 10.1177/1352458518810159. [Epub ahead of print]

PMID:
30381985
29.

Diet quality and risk of multiple sclerosis in two cohorts of US women.

Rotstein DL, Cortese M, Fung TT, Chitnis T, Ascherio A, Munger KL.

Mult Scler. 2018 Oct 23:1352458518807061. doi: 10.1177/1352458518807061. [Epub ahead of print]

PMID:
30351179
30.

Heterogeneity in association of remote herpesvirus infections and pediatric MS.

Nourbakhsh B, Rutatangwa A, Waltz M, Rensel M, Moodley M, Graves J, Casper TC, Waldman A, Belman A, Greenberg B, Goyal M, Harris Y, Kahn I, Lotze T, Mar S, Schreiner T, Aaen G, Hart J, Ness J, Rubin J, Tillema JM, Krupp L, Gorman M, Benson L, Rodriguez M, Chitnis T, Rose J, Candee M, Weinstock-Guttman B, Shao X, Barcellos L, James J, Waubant E; US Network of Pediatric MS Centers.

Ann Clin Transl Neurol. 2018 Sep 17;5(10):1222-1228. doi: 10.1002/acn3.636. eCollection 2018 Oct.

31.

Urban air quality and associations with pediatric multiple sclerosis.

Lavery AM, Waubant E, Casper TC, Roalstad S, Candee M, Rose J, Belman A, Weinstock-Guttman B, Aaen G, Tillema JM, Rodriguez M, Ness J, Harris Y, Graves J, Krupp L, Charvet L, Benson L, Gorman M, Moodley M, Rensel M, Goyal M, Mar S, Chitnis T, Schreiner T, Lotze T, Greenberg B, Kahn I, Rubin J, Waldman AT.

Ann Clin Transl Neurol. 2018 Sep 27;5(10):1146-1153. doi: 10.1002/acn3.616. eCollection 2018 Oct.

32.

Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study.

Zivadinov R, Medin J, Khan N, Korn JR, Chitnis T, Naismith RT, Alvarez E, Dwyer MG, Bergsland N, Carl E, Silva D, Weinstock-Guttman B; MS-MRIUS Study Group.

Mult Scler Relat Disord. 2019 Jan;27:65-73. doi: 10.1016/j.msard.2018.09.037. Epub 2018 Oct 3.

PMID:
30342416
33.

Use of newer disease-modifying therapies in pediatric multiple sclerosis in the US.

Krysko KM, Graves J, Rensel M, Weinstock-Guttman B, Aaen G, Benson L, Chitnis T, Gorman M, Goyal M, Krupp L, Lotze T, Mar S, Rodriguez M, Rose J, Waltz M, Charles Casper T, Waubant E; US Network of Pediatric MS Centers.

Neurology. 2018 Nov 6;91(19):e1778-e1787. doi: 10.1212/WNL.0000000000006471. Epub 2018 Oct 17.

PMID:
30333163
34.

Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta and glatiramer acetate.

Healy BC, Glanz BI, Zurawski JD, Mazzola M, Chitnis T, Weiner HL.

J Neurol Sci. 2018 Nov 15;394:127-131. doi: 10.1016/j.jns.2018.09.020. Epub 2018 Sep 17.

PMID:
30248571
35.

Brain and spinal cord MRI lesions in primary progressive vs. relapsing-remitting multiple sclerosis.

Dastagir A, Healy BC, Chua AS, Chitnis T, Weiner HL, Bakshi R, Tauhid S.

eNeurologicalSci. 2018 Jul 4;12:42-46. doi: 10.1016/j.ensci.2018.07.002. eCollection 2018 Sep.

36.

Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.

Chitnis T, Arnold DL, Banwell B, Brück W, Ghezzi A, Giovannoni G, Greenberg B, Krupp L, Rostásy K, Tardieu M, Waubant E, Wolinsky JS, Bar-Or A, Stites T, Chen Y, Putzki N, Merschhemke M, Gärtner J; PARADIGMS Study Group.

N Engl J Med. 2018 Sep 13;379(11):1017-1027. doi: 10.1056/NEJMoa1800149.

37.

Efficacy and safety of mycophenolate mofetil in progressive multiple sclerosis patients.

Fakih R, Matiello M, Chitnis T, Stankiewicz JM.

J Neurol. 2018 Nov;265(11):2688-2694. doi: 10.1007/s00415-018-9050-1. Epub 2018 Sep 10.

PMID:
30203314
38.

Identification of MS-specific serum miRNAs in an international multicenter study.

Regev K, Healy BC, Paul A, Diaz-Cruz C, Mazzola MA, Raheja R, Glanz BI, Kivisäkk P, Chitnis T, Jagodic M, Piehl F, Olsson T, Khademi M, Hauser S, Oksenberg J, Khoury SJ, Weiner HL, Gandhi R.

Neurol Neuroimmunol Neuroinflamm. 2018 Aug 20;5(5):e491. doi: 10.1212/NXI.0000000000000491. eCollection 2018 Sep.

39.

Quantitative MRI analysis of cerebral lesions and atrophy in post-partum patients with multiple sclerosis.

Khalid F, Healy BC, Dupuy SL, Chu R, Chitnis T, Bakshi R, Houtchens M.

J Neurol Sci. 2018 Sep 15;392:94-99. doi: 10.1016/j.jns.2018.06.025. Epub 2018 Jun 30.

PMID:
30031994
40.

Short Report: A Pilot Study of a Group Positive Psychology Intervention for Patients with Multiple Sclerosis.

Leclaire K, Cecil A, LaRussa A, Stuart F, Hemond CC, Healy BC, Chitnis T, Weiner H, Huffman J, Glanz BI.

Int J MS Care. 2018 May-Jun;20(3):136-141. doi: 10.7224/1537-2073.2017-002.

41.

Relapse Rate and MRI Activity in Young Adult Patients With Multiple Sclerosis: A Post Hoc Analysis of Phase 3 Fingolimod Trials.

Gärtner J, Chitnis T, Ghezzi A, Pohl D, Brück W, Häring DA, Karlsson G, Putzki N.

Mult Scler J Exp Transl Clin. 2018 May 25;4(2):2055217318778610. doi: 10.1177/2055217318778610. eCollection 2018 Apr-Jun.

42.

Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS.

Zivadinov R, Medin J, Khan N, Korn JR, Bergsland N, Dwyer MG, Chitnis T, Naismith RT, Alvarez E, Kinkel P, Cohan S, Hunter SF, Silva D, Weinstock-Guttman B; MS-MRIUS investigators.

J Neuroimaging. 2018 Jul;28(4):399-405. doi: 10.1111/jon.12518. Epub 2018 May 11.

PMID:
29749661
43.

Pediatric Neuromyelitis Optica Spectrum Disorders.

Gombolay GY, Chitnis T.

Curr Treat Options Neurol. 2018 May 2;20(6):19. doi: 10.1007/s11940-018-0502-9. Review.

PMID:
29721683
44.

Complexity of MS management in the current treatment era.

Chitnis T, Giovannoni G, Trojano M.

Neurology. 2018 Apr 24;90(17):761-762. doi: 10.1212/WNL.0000000000005399. No abstract available.

PMID:
29686111
45.

Early infectious exposures are not associated with increased risk of pediatric-onset multiple sclerosis.

Suleiman L, Waubant E, Aaen G, Belman A, Benson L, Candee M, Chitnis T, Gorman M, Goyal M, Greenberg B, Harris Y, Hart J, Kahn I, Krupp L, Lotze T, Mar S, Moodley M, Ness J, Nourbakhsh B, Rensel M, Rodriguez M, Rose J, Rubin J, Schreiner T, Tillema JM, Waldman A, Weinstock-Guttman B, Casper TC, Waltz M, Graves JS; Network of Pediatric Multiple Sclerosis Centers.

Mult Scler Relat Disord. 2018 May;22:103-107. doi: 10.1016/j.msard.2018.03.015. Epub 2018 Mar 26.

46.

Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis.

Raheja R, Regev K, Healy BC, Mazzola MA, Beynon V, Von Glehn F, Paul A, Diaz-Cruz C, Gholipour T, Glanz BI, Kivisakk P, Chitnis T, Weiner HL, Berry JD, Gandhi R.

Muscle Nerve. 2018 Aug;58(2):261-269. doi: 10.1002/mus.26106. Epub 2018 Mar 25.

47.

Fatty acid binding protein-4 is associated with disability in multiple sclerosis patients.

Bove R, Healy BC, Musallam A, Soltany P, Diaz-Cruz C, Sattarnezhad N, Glanz BI, Kivisäkk P, Miller KK, Chitnis T.

Mult Scler. 2019 Mar;25(3):344-351. doi: 10.1177/1352458517750768. Epub 2018 Jan 11.

PMID:
29320952
48.

The role of testosterone in MS risk and course.

Chitnis T.

Mult Scler. 2018 Jan;24(1):36-41. doi: 10.1177/1352458517737395. Review.

PMID:
29307293
49.

Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count.

Baharnoori M, Gonzalez CT, Chua A, Diaz-Cruz C, Healy BC, Stankiewicz J, Weiner HL, Chitnis T.

Mult Scler Relat Disord. 2018 Feb;20:51-57. doi: 10.1016/j.msard.2017.12.003. Epub 2017 Dec 14.

PMID:
29304497
50.

Evaluating the Association between Enlarged Perivascular Spaces and Disease Worsening in Multiple Sclerosis.

Cavallari M, Egorova S, Healy BC, Palotai M, Prieto JC, Polgar-Turcsanyi M, Tauhid S, Anderson M, Glanz B, Chitnis T, Guttmann CRG.

J Neuroimaging. 2018 May;28(3):273-277. doi: 10.1111/jon.12490. Epub 2017 Dec 11.

PMID:
29226505

Supplemental Content

Loading ...
Support Center